Why did the Russian cancer vaccine close its doors after it opened for trial?

Russia's new anti-cancer vaccine, called Enteromix, is a tumor-destroying vaccine that works on the 'Trojan horse' principle.

In February this year, Russian President Putin said that Russian scientists were close to creating a cancer vaccine that could soon be available to patients. Russia is now recruiting volunteers for clinical trials - Photo: NTR TRUST

According to a VNA reporter in Moscow on December 21, Russia recently announced the recruitment of volunteers for clinical trials of a new anti-cancer vaccine called Enteromix.

The vaccine, developed jointly by the National Medical Research Center of Radiology of the Russian Ministry of Health and other institutes, is claimed by Russia as a breakthrough in the fight against cancer.

Too many people signed up for the trial

To participate in the vaccine trial, send an email to vakcina-rak@nmicr.ru with the subject "Oncovaccine". The email must include full name and contact phone number; the latest medical report, including information about the treatment, test results and blood tests (general and biochemical).

However, on December 20, Dr. Andrei Kaprin, the chief oncologist of the Russian Ministry of Health, announced a temporary suspension of the selection due to the large number of applications.

According to preliminary estimates, the cost of producing one dose of the cancer vaccine is about 300,000 rubles (about 74 million VND). However, it is expected that Russia will provide the cancer vaccine to its people for free.

Explaining further about the new vaccine, Dr. Andrei Kaprin said that the Enteromix vaccine was developed mainly during the search for a COVID-19 vaccine, during which the vaccine demonstrated excellent anti-tumor properties.

The doctor also informed about the main approaches in the development of Russian cancer vaccines, including:

- Tumor-killing vaccines (Enteromix vaccine belongs to this category), work on the "Trojan horse" principle: viruses or other substances will attach to the carrier cells (proteins) to destroy tumor cells. The carrier carries the "warhead" directly to the tumor.

- Anti-oncovaccine is a vaccine that is specifically selected for tumors. It will react with tumors in humans. That is, by surgical method we remove the tumor, select the vaccine for it and then inject the vaccine into the tumor and into the vascular bed.

- mRNA vaccines are based on decoding tumor DNA. This is a personalized vaccine that trains the immune system to fight the cancer itself. This approach is similar to the technology used to create COVID-19 vaccines.

Phase 1 is to test the safety of the vaccine in a small group of volunteers. In the case of the Enteromix vaccine, efficacy is also being evaluated in selected patients.

The second phase investigates the optimal dose of the vaccine and efficacy in a larger group of patients.

Phase three involves thousands of patients, testing the vaccine's effectiveness against standard treatments or a placebo. This phase is the longest and can take several years.

Russian cancer researchers caution that the trial is in its early stages and results will be known later. Patients are advised that while the vaccine is promising, any existing treatments and support should not be ruled out in treatment.

Opening new horizons in the fight against cancer

According to the website of the National Medical Research Center of Radiology of the Ministry of Health of Russia (NMRRC), the center is conducting extensive scientific research in two areas at the same time:

The first is the EnteroMix anti-cancer vaccine, which is based on a combination of four non-pathogenic viruses that can destroy malignant cells while activating the patient's anti-tumor immunity. The center cooperated with the Engelhardt Institute of Biomedicine of the Russian Academy of Sciences to develop the vaccine.

The second area is a “personalized” mRNA vaccine based on a personalized approach, developed in collaboration with the Gamaleya Institute. Accordingly, after analyzing each tumor, a unique vaccine is created for the patient that can “teach” the immune system to recognize cancer cells.

"We believe that these vaccines will open new horizons in the fight against cancer and save thousands of lives," the NMRRC wrote, calling it the result of research by "talented Russian scientists."

Source: https://tuoitre.vn/vi-sao-vac-xin-chong-ung-thu-cua-nga-moi-moi-moi-moi-cong-tim-nguoi-chiu-thu-thi-da-phai-dong-20241221092744833.htm